Uncategorized

Replimune to ride wave of physician support to launch advanced melanoma therapy

Published

1 day ago

on

August 7, 2026

By

Temp User

Analysts expect Replimune’s newly approved Tudriqev to reach $1.3 billion in peak sales in 2035.

Related Topics:

Leave a Reply

Fierce Biotech4 months ago

Scientists turn pig semen extract into eye drops that kill cancer in mice
Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Endpoints News5 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized5 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Steph Curry finally got the contract he deserves from the Warriors

Exit mobile version